PharmaSGP Holding SE
PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil … Read more
PharmaSGP Holding SE (PSG) - Total Liabilities
Latest total liabilities as of March 2025: €81.51 Million EUR
Based on the latest financial reports, PharmaSGP Holding SE (PSG) has total liabilities worth €81.51 Million EUR as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PharmaSGP Holding SE - Total Liabilities Trend (2014–2024)
This chart illustrates how PharmaSGP Holding SE's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PharmaSGP Holding SE Competitors by Total Liabilities
The table below lists competitors of PharmaSGP Holding SE ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Generic Sweden publ AB
ST:GENI
|
Sweden | Skr38.55 Million |
|
Iz Hayvancilik Tarim ve Gida Sanayi Ticaret AS
IS:IZINV
|
Turkey | TL39.95 Million |
|
Southern Energy Corp
V:SOU
|
Canada | CA$35.51 Million |
|
Kainos Medicine Inc
KQ:284620
|
Korea | ₩4.18 Billion |
|
HeraMED Limited
F:1I4
|
Germany | €1.71 Million |
|
Prestige Wealth Inc.
NASDAQ:AURE
|
USA | $323.27K |
|
TREJHARA SOLUTIONS LIMITED
NSE:TREJHARA
|
India | ₹259.53 Million |
|
Ecocab Co. Ltd
KQ:128540
|
Korea | ₩60.76 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down PharmaSGP Holding SE's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PharmaSGP Holding SE's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PharmaSGP Holding SE (2014–2024)
The table below shows the annual total liabilities of PharmaSGP Holding SE from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €82.31 Million | -10.09% |
| 2023-12-31 | €91.55 Million | -6.60% |
| 2022-12-31 | €98.01 Million | +5.32% |
| 2021-12-31 | €93.06 Million | +592.58% |
| 2020-12-31 | €13.44 Million | +64.65% |
| 2019-12-31 | €8.16 Million | -63.05% |
| 2017-12-31 | €22.09 Million | -1.69% |
| 2016-12-31 | €22.47 Million | -4.22% |
| 2015-12-31 | €23.46 Million | +16.53% |
| 2014-12-31 | €20.13 Million | -- |